An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer. [electronic resource]
Producer: 20171121Description: 383-389 p. digitalISSN:- 1556-1380
- Adenocarcinoma -- drug therapy
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Biomarkers, Tumor -- metabolism
- Carcinoma, Large Cell -- drug therapy
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Cisplatin -- administration & dosage
- Female
- Follow-Up Studies
- Humans
- Lung Neoplasms -- drug therapy
- Male
- Middle Aged
- Neoplasm Staging
- Pemetrexed -- administration & dosage
- Prognosis
- Survival Rate
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.